Esmolol 是一种超短效心脏选择性 β1-肾上腺素 (β1-adrenergic) 能阻滞剂,通过激活 NK1 受体 (Neurokinin 1 Receptor) 发挥抗心律失常作用,可减轻复苏后心肌功能障碍,并通过抑制醛糖还原酶 (aldose reductase)、晚期糖基化终产物的产生以及促进成纤维细胞的迁移来改善糖尿病的伤口愈合,可用于研究心律失常等心脏疾病以及糖尿病足溃疡。
产品编号: MS-B86299 CAS No.: 81147-92-4 分子式: C16H25NO4 分子量: 295.37
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Esmolol 是一种超短效心脏选择性 β1-肾上腺素 (β1-adrenergic) 能阻滞剂,通过激活 NK1 受体 (Neurokinin 1 Receptor) 发挥抗心律失常作用,可减轻复苏后心肌功能障碍,并通过抑制醛糖还原酶 (aldose reductase)、晚期糖基化终产物的产生以及促进成纤维细胞的迁移来改善糖尿病的伤口愈合,可用于研究心律失常等心脏疾病以及糖尿病足溃疡。

生物实验数据

生物活性 Esmolol is an ultra-short-acting cardioselective β1-adrenergic blocker that exerts its antiarrhythmic effects by activating the NK1 receptor (Neurokinin 1 Receptor), alleviates post-resuscitation myocardial dysfunction, and improves diabetic wound healing by inhibiting aldose reductase and advanced glycation end product formation and promoting fibroblast migration, and can be used to study cardiac diseases such as arrhythmias as well as diabetic foot ulcers.
IC50 & Target

β adrenergic receptor

 

Caspase 3

 

体外研究
(In Vitro)

Esmolol hydrochloride (0-1 mM) 可抑制醛糖还原酶活性,IC50 估计值为 150 µM,并可抑制红细胞中 59% 的山梨醇形成。
Esmolol hydrochloride (0.5-1 mM,10 分钟) 可抑制晚期糖基化终产物 (AGEs) 的形成。
Esmolol hydrochloride (0.01-1000 µM,8-48 小时) 可促进 HFF-1、Ea.hy926 和 HaCaT 细胞的迁移能力,且无细胞毒性。

Cell Migration Assay

Cell Line: HFF-1, Ea.hy926, HaCaT cells
Concentration: 0.01 μM, 0.1 μM, 1 μM, 10 μM, 50 μM, 100 μM, 500 μM, 100 μM
Incubation Time: 8 h, 14 h, 16 h, 22 h, 24 h, 42 h, 48 h
Result: Promoted the ability to migrate, with low migration at 100 and 500 µM.
体内研究
(In Vivo)

Esmolol hydrochloride (7%-20%,局部应用,每日两次) 可改善 Streptozotocin (MS-Q80520) 诱发的糖尿病无毛大鼠的 NO 诱导、胶原周转和羟脯氨酸水平,并改善其重塑和伤口愈合。
Esmolol (10 mg/kg,0.3 mL,静脉注射,一次) 在永久性冠状动脉闭塞 (CAO) 大鼠模型中,通过上调 NK1 受体表现出抗心律失常作用。
Esmolol (300 μg/kg,肾上腺素20 μg/kg,静脉注射,一次) 在近交系五指山小型猪中通过减少凋亡来保护心肌组织,改善复苏后心肌功能障碍。

Animal Model: Streptozotocin-induced (35 mg/kg/day for 5 consecutive days) diabetic hairless rats model
Dosage: 7, 14, and 20%
Administration: topical applied, twice daily
Result: Increased the total nitrite content and NO level in wound tissue by 44% and 112% in the G14 group compared with the diabetic control group and the vehicle control group, and by 8% and 59% in the G20 group compared with the diabetic control group and the vehicle control group.
Improved collagen content, hydroxyproline levels, increased hydroxyproline levels by 22% and 44% in the G14 group, and 21% and 43% in the G20 on day 7; increased hydroxyproline levels by 6% and 13% in the G14 group, increased hydroxyproline levels by 41% and 49% in the G20 group on day 14, compared with the diabetic control and vehicle control groups.
Improved healing in G20 group and closer to normal intact diabetic skin (wounds were not completely closed on day 19).
Animal Model: CAO Male Sprague-Dawley rats (weighing 260 g-280 g) model
Dosage: 10 mg/kg, in 0.3 mL
Administration: i.v., once
Result: Reduced ventricular ectopic beat (VEB) by 66%, and reduced the incidence, number, and duration of VT and VF by 66%, 92%, and 95%, respectively.
Attenuated the arrhythmogenic effects of D-SP, reducing the VEB by 45%, the morbidity rate, the episodes and the durations of VT & VF by 86%, 62% and 50% respectively, in 9-23 min following the coronary artery occlusion (CAO) (14 min-28 min after the injection of esmolol).
Increased NK1-R mRNA and protein, by 72% and 19% respectively, at 15 min after the CAO.
Animal Model: Inbred Wuzhishan miniature pigs (12-14 months of age, 30 kg) model
Dosage: 300 μg/kg with Epinephrine (MS-K49404) 20 μg/kg
Administration: i.v., once
Result: Reduced the number of shocks, defibrillation energy, return of spontaneous circulation (ROSC) time and 4 h heart rate (HR), and increased the 24 h survival rate, 4-6 h CO values, 4 h mean aortic pressure (MAP) value, and 4 h left ventricular dp/dtmax.
Reduced serum cTnI, lactate concentrations and, myocardial malondialdehyde (MDA) content, increased ATPase and SOD levels.
Reduced caspase-3 proteolytic activation, mRNA levels, and TUNEL-positive cells, and attenuated apoptotic effects by upregulating Bcl-2/Bax protein levels.

化学信息

分子量 295.37
分子式 C16H25NO4
CAS No. 81147-92-4

储存&溶解度

溶解度信息
DMSO: Soluble
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础